公开(公告)号：WO2021030179A1

公开(公告)日：2021-02-18

申请号：PCT/US2020/045365

申请日：2020-08-07

Applicant: AMGEN INC.

Inventor： CHRISTIAN, Twinkle, R.

IPC: C07K16/22 ,  A61P19/10

Abstract: The present disclosure is directed to pharmaceutical compositions comprising an anti-sclerostin antibody.

公开(公告)号：WO2018067987A1

公开(公告)日：2018-04-12

申请号：PCT/US2017/055620

申请日：2017-10-06

Applicant: AMGEN INC.

Inventor： TERAN, Alona ,  MUNAIM, Qahera ,  KHALAF, Nazer ,  KAUSHIK, Rahul, Rajan ,  CLOGSTON, Christi, L. ,  CHRISTIAN, Twinkle, R. ,  CALLAHAN, William, J.

IPC: A61K39/00 ,  A61K47/22

Abstract: Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.

Abstract translation: 本文描述了包含N-甲基吡咯烷酮（NMP）的治疗性蛋白质制剂，涉及降低药物制剂粘度的方法和涉及使用NMP稳定药物制剂的方法。

公开(公告)号：WO2022056455A1

公开(公告)日：2022-03-17

申请号：PCT/US2021/050238

申请日：2021-09-14

Applicant: AMGEN INC.

Inventor： MCAULEY, Arnold ,  TREUHEIT, Michael, J. ,  CHRISTIAN, Twinkle, R. ,  JAGANNATHAN, Bharadwaj

IPC: A61K9/19 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K39/395 ,  C07K14/00

Abstract: Disclosed herein are methods of preparing lyophilized formulations comprising a protein, such as an antibody or a bispecific antibody construct, that exhibits improved storage stability.

公开(公告)号：WO2021222355A1

公开(公告)日：2021-11-04

申请号：PCT/US2021/029560

申请日：2021-04-28

Applicant: AMGEN INC.

Inventor： CHRISTIAN, Twinkle, R. ,  JAGANNATHAN, Bharadwaj ,  DYKSTRA, Andrew

IPC: A61K39/395

Abstract: The present disclosure describes stable aqueous formulations comprising, e.g., a bispecific antibody construct, a buffer, a saccharide and a surfactant, the formulation having a pH 4.8-5.5.

公开(公告)号：WO2021222347A1

公开(公告)日：2021-11-04

申请号：PCT/US2021/029545

申请日：2021-04-28

Applicant: AMGEN INC.

Inventor： CHRISTIAN, Twinkle, R. ,  JAGANNATHAN, Bharadwaj

IPC: A61K39/395

Abstract: Described herein are stable high concentration bispecific antibody construct formulations, wherein the formulations have less than 2% high molecular weight species of the bispecific antibody construct in the formulation under storage conditions at various time points.

公开(公告)号：WO2012135035A1

公开(公告)日：2012-10-04

申请号：PCT/US2012/030364

申请日：2012-03-23

Applicant: AMGEN INC. ,  CLOGSTON, Christi, L. ,  CHRISTIAN, Twinkle, R. ,  OSSLUND, Timothy, D. ,  FREEMAN, Elisabeth

Inventor： CLOGSTON, Christi, L. ,  CHRISTIAN, Twinkle, R. ,  OSSLUND, Timothy, D. ,  FREEMAN, Elisabeth

IPC: C07K16/22 ,  A61K39/395

CPC classification number: C07K16/18 ,  A61K39/39591 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/56 ,  C07K2317/76

Abstract: Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.

Abstract translation: 本文描述了抗硬化蛋白抗体结晶，制备这种抗体结晶的方法和包含抗体晶体的制剂。

公开(公告)号：WO2021081321A1

公开(公告)日：2021-04-29

申请号：PCT/US2020/057054

申请日：2020-10-23

Applicant: AMGEN INC.

Inventor： POMPE, Cornelius ,  CLARK, Nicholas, J. ,  QI, Wei ,  MCAULEY, Arnold, J. ,  SCHNEIDER, Michael ,  WU, Chia-Jung ,  CHRISTIAN, Twinkle, R. ,  FRANEY, Heather, N. ,  JAGANNATHAN, Bharadwaj ,  ABEL, Jeffrey ,  DIETZEL, Franz

IPC: G01N24/08 ,  G01N33/15 ,  A61M5/142

Abstract: An approach for determining material compatibility for components of a drug delivery system is provided that includes using surface zeta-potential analytical method to evaluate surface interactions between a desired molecule and at least one material present within a given IV-bag system.

公开(公告)号：WO2019157340A1

公开(公告)日：2019-08-15

申请号：PCT/US2019/017294

申请日：2019-02-08

Applicant: AMGEN INC.

Inventor： CHRISTIAN, Twinkle, R. ,  SHAN, Daxian

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/40 ,  A61K9/00

Abstract: The present disclosure describes low pH formulations comprising, e.g., an antigen- binding protein that binds CD3, at least one buffer agent, at least one saccharide and at least one surfactant.